Veru is a Miami-based drug developer working on enobosarm for obesity and sabizabulin for inflammatory heart disease. VERU reports earnings on Thu, Nov 26, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 6 | WestPark Capital | Initiated | Buy | |
| Jun 4 | Canaccord Genuity | Maintained | Buy |
Seasonality
How VERU has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in VERU in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VERU is in one of them and how their past VERU trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered VERU in an article yet. Here's the latest on the wider market.
About Veru
Veru is a drug development company based in Miami, Florida. Its lead candidate, enobosarm, is an oral medicine designed for patients with obesity who take GLP-1 drugs, with the aim of helping them keep muscle while losing fat. Its second candidate, sabizabulin, is being studied as a treatment for inflammation in atherosclerotic cardiovascular disease, a condition in which fatty deposits build up in the arteries. The company's candidates are aimed at patients with these conditions and the doctors who treat them.
- Headquarters
- Miami, FL